Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Abstract A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2...

Full description

Bibliographic Details
Main Authors: Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter, Jim Bush, Oren Cohen
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Trials
Subjects:
COVID-19
SARS-CoV-2
Antiviral therapy
Ribonucleoside analog
Phase I
Accelerated start-up
Online Access:https://doi.org/10.1186/s13063-021-05538-5

Internet

https://doi.org/10.1186/s13063-021-05538-5

Similar Items